Trial
NCT06060587
Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Northwestern University
Collaborators
National Cancer Institute (NCI)
Condition
Prostate Cancer
Intervention
Docetaxel
Why stopped
PI left institution
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-22